Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Medicaid Reform Bill Could Mean More Whistleblowers At State Level

Executive Summary

A provision in the Senate's Medicaid reform bill that encourages states to pass qui tam laws could increase incentives for whistleblowers to file suits against pharmaceutical companies alleging rebate fraud

You may also be interested in...



Off-Label Dissemination Keeps FDA Stuck Between Prosecutors And Firms

As industry weighs the potential impact of FDA's guidance on good reprint practices, stakeholders are suggesting alternate policy approaches that could give companies sufficient clarity on how to conduct off-label dissemination

Off-Label Dissemination Keeps FDA Stuck Between Prosecutors And Firms

As industry weighs the potential impact of FDA's guidance on good reprint practices, stakeholders are suggesting alternate policy approaches that could give companies sufficient clarity on how to conduct off-label dissemination

Rx Compliance Enforcement Is Moving Away From “FDA” Cases, Sheehan Says

CAMBRIDGE, Mass.-Due to FDA's diminishing influence over the direction of pharmaceutical regulatory enforcement, a comprehensive understanding of the compliance concerns for drug products should focus on existing case law to understand the dynamics of the enforcement landscape, New York Medicaid Inspector General James Sheehan said

Related Content

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel